Reliance Industries, through its subsidiary Reliance Strategic Business Ventures (RSBVL) has acquired the oncology-focused healthcare platform Karkinos for Rs 375 crore. The move would help expand its health services portfolio.
The acquisition was completed with the allotment of shares, involving RSBVL subscribing to Rs 10 crore in equity shares and Rs 365 crore in optionally fully convertible debentures of Karkinos on 27 December, 2024. Existing shares held by previous investors were cancelled as part of the approved resolution plan. Previous investors in Karkinos included Ewart Investments (a Tata Sons subsidiary), Reliance Digital Health (another Reliance Industries subsidiary), Mayo Clinic, Sundar Raman (Director at Reliance Foundation Youth Sports), and Ravi Kant (former MD of Tata Motors).
Karkinos provides technology-driven solutions for cancer detection, diagnosis, and management. In FY23, it reported a turnover of approx. Rs 22 crore. Karkinos aims to provide affordable end-to-end cancer care services has partnered with approx. 60 hospitals by December 2023. A subsidiary is also setting up a 150-bed multispecialty cancer hospital in Imphal, Manipur.
Future revenue streams are expected from Advanced Cancer Care Diagnostics and Research (ACCDR), corporate partnerships for early diagnosis, and cancer care hospitals.
